Scienture Holdings, Inc. (SCNX) stock forecast & analysis
3.86
NasdaqCM · USD
Up: +0.14, +3.8%
1 analysis
- Open
- 3.23
- Previous close
- 3.71
- Day range
- 3.23 – 4.14
- 52-week range
- 3.23 – 65.00
- Volume (shares)
- 162.44K
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 1.64M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 4.08
- Market cap
- 6.33M
Market Scanner’s AI analysis of Scienture Holdings, Inc. (SCNX), updated October 2026: SCNX's recent analyses covered Arbli™ formulary additions and commercial partnerships, juxtaposed with significant technical downtrends and negative profitability.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Scienture Holdings, Inc. (SCNX) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
SCNX's recent analyses covered Arbli™ formulary additions and commercial partnerships, juxtaposed with significant technical downtrends and negative profitability.
Recent analyses for SCNX, Scienture Holdings, Inc., examined positive developments including Arbli™ formulary additions to pediatric centers and expanded reach for REZENOPY™ through new distribution agreements. These were contrasted with a reverse stock split announcement. The reports also detailed significant technical downtrends, with the stock price trading well below key moving averages and indicators suggesting oversold conditions. Fundamentals indicated negative EPS, operating margins, and return on equity, alongside substantial net losses in recent fiscal years.
SCNX news & sentiment
News reports highlighted significant positive developments regarding SCNX's Arbli™ and REZENOPY™ drugs, detailing expanded institutional reach and new commercial partnerships. However, market sentiment was tempered by a recent reverse stock split announcement. Social media discussion was not covered in the provided notes.
SCNX technical picture
The stock price was trading significantly below its 50-day and 200-day simple moving averages, as well as its 10-day exponential moving average. Momentum indicators including the RSI, MFI, and MACD all suggested strong selling pressure and oversold conditions, with the price trading below the lower Bollinger Band.
Fundamentals
The company reported trailing twelve months revenue and gross profit, but also significant operating and net losses in recent fiscal years. Profitability metrics including EPS, operating margin, and return on equity were negative.
Factors discussed — upside
- Arbli™ added to formularies of three leading U.S. pediatric academic medical centers and hospitals.
- Expanded institutional reach for hypertension drug through new hospital adoptions.
- Broadened reach of REZENOPY™ drug to addiction treatment centers via new distribution agreement.
Factors discussed — risks
- Stock price significantly below 50-day and 200-day SMAs.
- RSI and MFI deep in oversold territory.
- MACD indicating bearish momentum.
- Negative EPS, Operating Margin TTM, and Return on Equity TTM.
- Significant operating and net losses reported in fiscal years 2024 and 2025.
- Commercial partnerships
- Technical indicators
- Profitability
- Market penetration
Summary updated .
SCNX technical indicators
Common technical indicators for SCNX, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 8.87 | Price below |
| 10-day exponential moving average | 5.40 | Price below |
| Relative strength index (14-day) | 12.61 | Oversold |
| MACD line (12/26/9) | -1.3679 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 3.64 – 10.32 | Price inside the bands |
Analyses
Recent SCNX.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Scienture Holdings, Inc.?
- The bull case for SCNX centers on recent commercial expansion, with Arbli™ being added to pediatric hospital formularies and REZENOPY™ broadening its reach through new distribution agreements.
- What are the risks for Scienture Holdings, Inc.?
- Risks for SCNX include significant technical downtrends indicated by oversold RSI and MFI, coupled with negative profitability metrics such as EPS, operating margins, and substantial net losses in recent fiscal years.
- Is Scienture Holdings, Inc. bullish or bearish?
- Recent AI analyses of Scienture Holdings, Inc. examined factors on both sides. Discussed upside: The bull case for SCNX centers on recent commercial expansion, with Arbli™ being added to pediatric hospital formularies and REZENOPY™ broadening its reach through new distribution agreements. Discussed risks: Risks for SCNX include significant technical downtrends indicated by oversold RSI and MFI, coupled with negative profitability metrics such as EPS, operating margins, and substantial net losses in recent fiscal years. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Scienture Holdings, Inc.?
- News reports highlighted significant positive developments regarding SCNX's Arbli™ and REZENOPY™ drugs, detailing expanded institutional reach and new commercial partnerships. However, market sentiment was tempered by a recent reverse stock split announcement. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Scienture Holdings, Inc.?
- Every analysis of Scienture Holdings, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh SCNX.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.